CS logo
small CS logo
Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly

Budapest, Hungary
Hospital in Budapest
Budapest, Ráth György u. 7-9, 1122

About Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
14
Puma Biotechnology, Inc.
4
Pfizer
3
Helsinn Healthcare SA
1
Total Rows: 4

Clinical Trials at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly


During the past decade, Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 14 clinical trials were completed, i.e. on average, 175% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years2211002200112200116622110044Started TrialsCompleted Trails201520162017201820192020202102468
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
2008-12-09
2018-06-01
Completed
105
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
2009-02-04
2018-06-03
Completed
233
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
2009-07-09
2019-10-04
Completed
2,840
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
2009-07-30
2010-05-31
Terminated
16
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
2009-08-21
2018-06-28
Completed
479
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
2010-01-26
2017-08-07
Completed
452
A Study of Vemurafenib in Participants With Metastatic Melanoma
2011-03-01
2016-02-24
Completed
3,219
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804

Rows per page:

1–22 of 22

Clinical Trials Sponsors and Collaborators


In terms of collaborators to trials, out of the total clinical trials conducted in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" #1 collaborator was "Breast International Group" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Parexel" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.
Created with Highcharts 11.1.0Top Leading SponsorsHoffmann-La Roche: 14Hoffmann-La Roche: 14Puma Biotechnology, Inc.: 4Puma Biotechnology, Inc.: 4Pfizer: 3Pfizer: 3Helsinn Healthcare SA: 1Helsinn Healthcare SA: 1

Created with Highcharts 11.1.0Top CollaboratorsBreast International Group: 1Breast International Group: 1Foundation Medicine, Inc.: 1Foundation Medicine, Inc.: 1Genentech, Inc.: 1Genentech, Inc.: 1Parexel: 1Parexel: 1

Clinical Trials Conditions at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly


According to Clinical.Site data, the most researched conditions in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" are "Breast Cancer" (11 trials), "Advanced Breast Cancer" (1 trials), "Basal Cell Carcinoma" (1 trials), "Breast Neoplasms" (1 trials) and "Cancer of Unknown Primary Site" (1 trials). Many other conditions were trialed in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" in a lesser frequency.

Clinical Trials Intervention Types at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly


Most popular intervention types in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" are "Drug" (21 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (8 trials), "Trastuzumab" (6 trials), "Capecitabine" (5 trials), "Pertuzumab" (5 trials) and "Atezolizumab" (4 trials). Other intervention names were less common.

Clinical Trials Genders at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly


The vast majority of trials in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" are 16 trials for "All" genders and 6 trials for "Female" genders.

Clinical Trials Status at Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly


Currently, there are NaN active trials in "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly, undefined suspended trials, and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 15Phase 3: 15Phase 2: 7Phase 2: 7Phase 1: 1Phase 1: 1

Created with Highcharts 11.1.0Trials StatusCompleted: 13Completed: 13Active, not recruiting: 4Active, not recruiting: 4Recruiting: 3Recruiting: 3Terminated: 2Terminated: 2